Log in

Alnylam Pharmaceuticals News Headlines (NASDAQ:ALNY)

$119.29
-3.00 (-2.45 %)
(As of 02/26/2020 06:00 AM ET)
Today's Range
$118.14
Now: $119.29
$124.26
50-Day Range
$114.65
MA: $121.87
$133.99
52-Week Range
$65.81
Now: $119.29
$134.51
Volume547,569 shs
Average Volume654,628 shs
Market Capitalization$13.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.47

Headlines

Alnylam Pharmaceuticals (NASDAQ ALNY) News Headlines

Source:
DateHeadline
Alnylam to Webcast Presentations at Upcoming March Investor ConferencesAlnylam to Webcast Presentations at Upcoming March Investor Conferences
finance.yahoo.com - February 25 at 7:40 AM
How biotech Alnylam plans to make a profit, and what stands in its wayHow biotech Alnylam plans to make a profit, and what stands in its way
finance.yahoo.com - February 24 at 7:23 AM
Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 34,765 Shares of StockInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 34,765 Shares of Stock
www.americanbankingnews.com - February 21 at 5:29 PM
Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare ConferenceAlnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 20 at 12:53 PM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Buy" from AnalystsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 19 at 3:15 PM
Alnylam completes enrollment in late-stage vutrisiran studyAlnylam completes enrollment in late-stage vutrisiran study
seekingalpha.com - February 18 at 12:46 PM
Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with PolyneuropathyAlnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy
www.marketwatch.com - February 18 at 12:46 PM
Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be ImportantIonis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important
seekingalpha.com - February 16 at 10:39 PM
Head to Head Analysis: Alnylam Pharmaceuticals (NASDAQ:ALNY) and Orexigen Therapeutics (NASDAQ:OREXQ)Head to Head Analysis: Alnylam Pharmaceuticals (NASDAQ:ALNY) and Orexigen Therapeutics (NASDAQ:OREXQ)
www.americanbankingnews.com - February 16 at 6:16 PM
Dyslipidemia Drugs Market - Rapid Growth at Deep Value Price | Merck, Pfizer, SanofiDyslipidemia Drugs Market - Rapid Growth at Deep Value Price | Merck, Pfizer, Sanofi
www.marketwatch.com - February 14 at 6:31 PM
RNAi for Therapeutic Market: Identifying key players and it s most promising pipeline therapeuticsRNAi for Therapeutic Market: Identifying key players and it 's most promising pipeline therapeutics
www.marketwatch.com - February 14 at 1:30 PM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Up 8.6% in JanuaryAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Up 8.6% in January
www.americanbankingnews.com - February 14 at 7:22 AM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Post Quarterly Sales of $93.23 MillionAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Post Quarterly Sales of $93.23 Million
www.americanbankingnews.com - February 13 at 3:02 AM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) COO Yvonne Greenstreet Sells 6,250 SharesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) COO Yvonne Greenstreet Sells 6,250 Shares
www.americanbankingnews.com - February 11 at 7:04 PM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) COO Yvonne Greenstreet Sells 9,892 SharesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) COO Yvonne Greenstreet Sells 9,892 Shares
www.americanbankingnews.com - February 11 at 7:04 PM
Akshay Vaishnaw Sells 23,708 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockAkshay Vaishnaw Sells 23,708 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
www.americanbankingnews.com - February 11 at 7:04 PM
Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells 30,000 Shares of StockInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells 30,000 Shares of Stock
www.americanbankingnews.com - February 11 at 7:04 PM
Zacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Announce Earnings of -$1.84 Per ShareZacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Announce Earnings of -$1.84 Per Share
www.americanbankingnews.com - February 11 at 6:55 PM
Thinking about trading options or stock in Alnylam Pharmaceuticals, Bed Bath & Beyond, Microsoft, NVIDIA, or Sprint?Thinking about trading options or stock in Alnylam Pharmaceuticals, Bed Bath & Beyond, Microsoft, NVIDIA, or Sprint?
www.prnewswire.com - February 11 at 12:40 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $75.00Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $75.00
www.americanbankingnews.com - February 11 at 9:59 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Research Coverage Started at Evercore ISIAlnylam Pharmaceuticals (NASDAQ:ALNY) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - February 10 at 6:59 AM
Cowen Reiterates Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)Cowen Reiterates Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
www.americanbankingnews.com - February 9 at 9:44 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly  Earnings Results, Misses Expectations By $0.22 EPSAlnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results, Misses Expectations By $0.22 EPS
www.americanbankingnews.com - February 7 at 7:03 PM
Alnylams (ALNY) Q4 Earnings Miss Estimates, Sales BeatAlnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
finance.yahoo.com - February 7 at 12:50 PM
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales BeatAlnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
finance.yahoo.com - February 7 at 12:50 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Lowered to $148.00 at Morgan StanleyAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Lowered to $148.00 at Morgan Stanley
www.americanbankingnews.com - February 7 at 10:43 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Buy" Rating from Chardan CapitalAlnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Buy" Rating from Chardan Capital
www.americanbankingnews.com - February 7 at 8:31 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Buy" Rating from Needham & Company LLCAlnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - February 7 at 8:08 AM
Edited Transcript of ALNY earnings conference call or presentation 6-Feb-20 1:30pm GMTEdited Transcript of ALNY earnings conference call or presentation 6-Feb-20 1:30pm GMT
finance.yahoo.com - February 7 at 7:49 AM
Alnylam Beats Revenue Estimates, but Misses on EarningsAlnylam Beats Revenue Estimates, but Misses on Earnings
www.fool.com - February 6 at 4:42 PM
Alnylam Pharmaceuticals EPS misses by $0.25, beats on revenueAlnylam Pharmaceuticals EPS misses by $0.25, beats on revenue
seekingalpha.com - February 6 at 4:42 PM
BRIEF-Alnylam Pharmaceuticals Reports Q4 Net Product Revenues Of $55.9 MlnBRIEF-Alnylam Pharmaceuticals Reports Q4 Net Product Revenues Of $55.9 Mln
www.msn.com - February 6 at 11:42 AM
Alnylam Pharma Posts Wider Loss In Q4 - Quick FactsAlnylam Pharma Posts Wider Loss In Q4 - Quick Facts
www.nasdaq.com - February 6 at 11:42 AM
Q4 sales of Alnylams Onpattro up 361%Q4 sales of Alnylam's Onpattro up 361%
seekingalpha.com - February 6 at 11:42 AM
Alnylam Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call PresentationAlnylam Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 6 at 11:42 AM
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period ActivityAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
finance.yahoo.com - February 6 at 11:42 AM
Traders Purchase High Volume of Alnylam Pharmaceuticals Put Options (NASDAQ:ALNY)Traders Purchase High Volume of Alnylam Pharmaceuticals Put Options (NASDAQ:ALNY)
www.americanbankingnews.com - February 6 at 6:44 AM
Alnylam Pharmaceuticals Q4 Earnings PreviewAlnylam Pharmaceuticals Q4 Earnings Preview
seekingalpha.com - February 5 at 5:37 PM
In the highest ranks of Mass. corporate leadership, women still scarceIn the highest ranks of Mass. corporate leadership, women still scarce
finance.yahoo.com - February 5 at 5:37 PM
European advisory group backs Alnylams givosiran for AHPEuropean advisory group backs Alnylam's givosiran for AHP
seekingalpha.com - January 31 at 9:11 AM
Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and AdolescentsAlnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents
finance.yahoo.com - January 31 at 9:11 AM
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q4 Earnings Expected to DeclineEarnings Preview: Alnylam Pharmaceuticals (ALNY) Q4 Earnings Expected to Decline
finance.yahoo.com - January 30 at 5:12 PM
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial ResultsAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - January 27 at 5:38 PM
Noteworthy Friday Option Activity: ALNY, EHTH, PBYINoteworthy Friday Option Activity: ALNY, EHTH, PBYI
www.nasdaq.com - January 17 at 5:17 PM
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%?Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%?
finance.yahoo.com - January 16 at 8:40 AM
Alexion pushes high-risk, high-reward ALS strategy amid competitive pressureAlexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
www.bizjournals.com - January 15 at 1:13 PM
Alnylam Pharmaceuticals (ALNY) Presents At 38th Annual J.P. Morgan Healthcare Conference - SlideshowAlnylam Pharmaceuticals (ALNY) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 14 at 5:11 PM
Alnylam Pharmaceuticals Beats Again, But The Bar Keeps Moving HigherAlnylam Pharmaceuticals Beats Again, But The Bar Keeps Moving Higher
seekingalpha.com - January 14 at 2:01 PM
Drugmakers getting creative over ways to pay for pricey medsDrugmakers getting creative over ways to pay for pricey meds
seekingalpha.com - January 13 at 3:49 PM
Alnylam Provides Preliminary Q4 Sales for Onpattro & GivlaariAlnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
www.nasdaq.com - January 13 at 3:49 PM
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: What is a death cross?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel